KALA · Kala Bio Inc
United States · RS rating 1 · As of 2026-10-14
| Price | 0.19 USD |
|---|---|
| 1-day change | -27.7% |
| RS rating (overall / 1M / 3M / 12M) | 1 / 2 / 2 / 1 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 11 / 45 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +37.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +99.8% |
| Market cap (USD) | $143.1M |